A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement

Soo Youn Lee, Myung Hyun Nam, Soo Kim June, Jong Won Kim

    Research output: Contribution to journalArticlepeer-review

    6 Citations (Scopus)

    Abstract

    We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient with CYP2C9*3/*4. A 73-yr-old woman with atrial fibrilation was taking warfarin. She attained a high prothrombin time international normalized ratio (INR) at the standard doses during the induction of anticoagulation and extremely low dose of warfarin (6.5 mg/week) was finally chosen to reach the target INR. Genotyping for CYP2C9 revealed that this patient had a genotype CYP2C9*3/*4. This is the first Korean compound heterozygote for CYP2C9*3 and *4. This case suggests the clinical usefulness of pharmacogenetic testing for individualized dosage adjustments of warfarin.

    Original languageEnglish
    Pages (from-to)557-559
    Number of pages3
    JournalJournal of Korean medical science
    Volume22
    Issue number3
    DOIs
    Publication statusPublished - 2007

    Keywords

    • Cytochrome P-450 CYP2C9
    • Pharmacogenetics
    • Polymorphism
    • Prothrombin time
    • Warfarin

    ASJC Scopus subject areas

    • Medicine(all)

    Fingerprint

    Dive into the research topics of 'A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement'. Together they form a unique fingerprint.

    Cite this